GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases

Company Records Steep Sales Decline For Shingles Vaccine in Q1

A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.

Shingles_1200
GSK forecasts stronger sales for its shingles vaccine, Shingrix, in the latter half of 2021 and 2022 • Source: Shutterstock

GlaxoSmithKline plc is anticipating that demand for its shingles vaccine, depressed over the past year due to COVID-19, will pick up again in the second half of the year and 2022; the company is looking toward that vaccine resilience as well as pipeline development to carry it past its pandemic depression.

The London-based drug maker announced its first quarter earnings on 28 April, with sales coming in well below analysts’ expectations...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.